In addition, lenalidomide has been shown to downregulate the expression of immune checkpoint molecules such as PD-L1 in lymphoma and myeloma cells leading to increased formation of lytic immune synapses and anti-tumor cytotoxicity by NK and CD8+ T cells [43]. The gene discussed is CD8A; the disease is neoplasm.